FDA Approves Subcutaneous Atezolizumab Plus Hyaluronidase-tqjs in Multiple Soft Tumor Indications
 |
|
BREAKING NEWS
|
| FDA Approves Subcutaneous Atezolizumab Plus Hyaluronidase-tqjs in Multiple Soft Tumor Indications Patients with certain solid tumors may be eligible for subcutaneous atezolizumab and hyaluronidase-tqjs, which is now approved by the FDA. |
|